Asana Inc. vs Eli Lilly And Co — how do they compare? Asana Inc. trades at $8.83 (market cap $2.13B), while Eli Lilly And Co trades at $1,205 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 507× Asana Inc.'s market cap, and Eli Lilly And Co pays a 0.57% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | LLY | |
|---|---|---|
Market Cap | $2.13B | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $1.24K |
52-Week Low | $5.46 | $639.43 |
Enterprise Value | $1.96B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.23, down slightly by 0.32% today. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, revenue growth is robust with fiscal 2025 revenue reaching $723.88 million, but the company remains unprofitable with a net loss of $255.54 million. Recent news highlights AI product innovation and a strategic partnership with Norway's sovereign wealth fund, signaling positive business momentum.
The outlook for Asana is mixed. Analyst consensus leans bullish with a $10.33 price target, but persistent losses and intense competition from tech giants pose significant risks. Upside potential hinges on continued revenue growth and path to profitability, while downside risks include margin pressure and execution challenges in a competitive SaaS market.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →